MedTrace Logo

Markers of Pubertal Suppression During Therapy for Precocious Puberty

NCT02006680 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 4

Last updated 2018-10-15

No results posted yet for this study

Summary

The best way to measure whether treatment of children with central precocious puberty is working is to do a hormone stimulation test (leuprolide stimulation test) that requires injection of a medication and multiple blood draws to see if the hormonal response is suppressed (blocked). The hypothesis of this study is that random measurement of the free alpha subunit of pituitary glycoprotein, a protein related to the pituitary hormones that stimulate puberty, will provide an adequate alternative to the leuprolide stimulation testfor monitoring efficacy of pubertal suppression with Supprelin LA®.

Conditions

  • Central Precocious Puberty

Sponsors & Collaborators

  • Endo Pharmaceuticals

    collaborator INDUSTRY

  • Atlantic Center for Research

    collaborator UNKNOWN

  • Goryeb Children's Hospital

    collaborator UNKNOWN

  • University of Minnesota

    lead OTHER

Principal Investigators

  • Bradley S Miller, MD, PhD · University of Minnesota

Eligibility

Min Age
3 Years
Max Age
9 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02006680 on ClinicalTrials.gov